Study on the efficacy of dietary supplements in the STAM™ model published in Cell Death & Disease.

SMC is proud to announce that J2H biotech (KOR) has published the results of their study using our pre-clinical services with STAM™ model in Cell Death & Disease.



Inhibition of 11β-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH

(Lee et al., Cell Death Dis . 2022)


This paper shows the results of a drug efficacy study that used our proprietary NASH model called STAM™ model.

To give you a little background on this model, the STAM™ mice have a diabetic background and follow the same disease progression that human patients do. They begin to develop steatosis at 6 weeks, then NASH at 8 weeks followed by liver fibrosis at 12 weeks, with the final stage, HCC, developing between 16 and 20 weeks.


In this paper, J2H-1702, a 11β-hydroxysteroid dehydrogenase type 1 inhibitor, was administered to the STAM™ mice from the steatosis phase to the late NASH phase.

In the liver of the J2H-1702-treated group, the inflammation score, which indicates the level of inflammatory cell infiltration, the level of fibrosis in the central venous zone, and Timp-1 mRNA expression levels were suppressed compared to the vehicle group. Furthermore, these anti-inflammatory and anti-fibrotic effects of J2H-1702 tend to be higher than those of the obeticholic acid (OCA)-treated group, a candidate drug for NASH.

It was found that J2H-1702 was successful in suppressing liver fibrosis and inflammation, as well as improving dyslipidemia and diabetes in vivo by inhibiting 11βHSD1 (Oh et al., Eur J Pharmacol. 2015).


It is not uncommon for NASH to develop in patients who suffer from diabetes (Younossi et al., J Hepatol. 2019). Therefore, it is thought that compounds which can successfully improve or prevent diabetes and associated dyslipidemia could be an effective way to prevent and treat NASH.


Are you considering conducting a study to evaluate the efficacy of your compound in NASH? Then why not consider testing it in the STAM™ model.

We have a wealth of experience when it comes to using the STAM™ model to evaluate a compounds effect in diseases related to inflammation, metabolism, and fibrosis. We would be happy to use our experience to help you create the perfect study design for your project.


If you are interested in using the STAM™ model, or any of our many other models, please feel free to contact us.